<div>
  <ul>
    <li>
      <p>
        Biogen has announced the acquisition of Human Immunology Biosciences (HI-Bio), a biotechnology firm specializing in providing targeted therapies for severe immune-mediated diseases. The transaction was valued at USD 1.15 billion, with potential milestone payments up to USD 650 million. The acquisition is planned to be finalized in the third quarter of 2024.
      </p>
    </li>
    <li>
      <p>
        Post-acquisition, Biogen will gain ownership of HI-Bio&rsquo;s lead candidate felzartamab, a late-stage asset for renal diseases. Biogen aims to combine HI-Bio&rsquo;s expertise with its own resources to further develop this program as well as develop novel therapies. The candidate has been granted FDA breakthrough therapy designation and orphan drug designation for the treatment of primary membranous nephropathy.
      </p>
    </li>
    <li>
      <p>
        Biogen is a biotechnology company specializing in the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases. Biogen's portfolio includes treatments for multiple sclerosis such as Avonex, Tysabri, Tecfidera, and Vumerity. The company also markets Spinraza for spinal muscular atrophy and Aduhelm for Alzheimer's disease. 
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.reuters.com/markets/deals/biogen-buy-human-immunology-biosciences-up-18-bln-deal-2024-05-22/">
      <b>Press release</b>
    </a>
  </p>
  <p>
    <a href="https://www.biopharminternational.com/view/biogen-boosts-immunology-portfolio-with-1-8-billion-acquisition-of-hi-bio">
      <b>BioPharm International</b>
    </a>
  </p>
  <p>
  </p>
</div>


Precision Medicine

INCUMBENTS_PRESENT

<div>
 <p>Biogen, a notable biotechnology company renowned for developing treatments for neurological and neurodegenerative diseases, has publicized the acquisition of Human Immunology Biosciences (HI-Bio). HI-Bio is a distinct biotechnology organization that offers targeted treatments for harsh immune-mediated diseases. The entire transaction value sums up to USD 1.15 billion, not excluding potential milestone expenses that could elevate to USD 650 million. The acquisition's expected culmination date is set in the third quarter of 2024.</p>
 <p>Upon finalizing the acquisition, Biogen will effectively become the owner of HI-Bio's chief candidate felzartamab, a late-stage entity earmarked for renal diseases. Biogen's strategic intent is to unite HI-Bio's unique knowledge and skill with Biogen's substantial resources. The goal is to refine the development program of the candidate and create pioneering therapies. In recognition of its progressive potential, Felzartamab has been privileged to receive FDA breakthrough therapy endorsement and an orphan drug designation reserved for counteracting primary membranous nephropathy.</p>
 <p>It's worth mentioning that Biogen excels in uncovering, evolving, and delivering treatments for neurological along with neurodegenerative diseases. Their extensive portfolio comprises therapies such as Avonex, Tysabri, Tecfidera, and Vumerity utilized effectively in handling multiple sclerosis. Other known products marketed by Biogen include Spinraza prescribed for spinal muscular atrophy and Aduhelm for mitigating Alzheimer's disease.</p>
</div>

Biogen to acquire Human Immunology Biosciences for USD 1.15 billion to expand its pipeline

Retail investors demanding sophisticated passive investment strategies are looking for an edge.

Retail Trading Infrastructure

<div>
 
 <p>Online trading platform Robinhood has introduced joint investment accounts. This feature lets users manage investments collaboratively and simplifies the investment process by consolidating financial assets into one account.</p>
 <p>The user-friendly joint investment account merges individual accounts, enables shared access, eases fund transfers, and provides easy switching between individual and joint accounts.</p>
 <p>With no extra charges, Robinhood aims to offer users additional financial growth opportunities by including benefits like a 1% deposit boost and a 5% APY on non-invested cash in the joint investment accounts.</p>
 
</div>

Robinhood launches joint investment accounts

PROMINENT_CATEGORY

<div>
 <p>Online trading platform eToro, based in Israel, has formed a partnership with the London Stock Exchange. This collaboration aims at offering users access to over 1,000 additional UK stocks and improving the quality of market data.</p>
 <p>This partnership will phase in the inclusion of more UK stocks to eToro's platform over the forthcoming months, growing from their existing offering of over 400 listed UK companies. eToro aims to enhance the trading experience for its global clientele, comprising of 3.8 million registered UK users. This enhancement will involve offering access to smaller stocks and better quality pricing data.</p>
 <p>This joint endeavor is a part of the strategies of eToro to tailor their offerings for the UK market. The strategy is in line with the prior launch of its ISA product and the provision for UK users to directly invest from GBP-denominated eToro Money accounts.</p>
</div>

eToro partners with London Stock Exchange to expand UK stock offerings

Generating, collecting, and analyzing enterprise data will never be the same.

Edge Computing

<div>
 
 <p>StorMagic, a provider of edge computing, has received an investment from Palatine Growth Credit Fund. The amount was not disclosed.</p>
 <p>The investment will be used to support the company's growth.</p> 
 <p>Established in 2006, StorMagic offers edge computing solutions, which includes software-defined storage and hyper-converged infrastructure specifically designed for edge environments, enabling businesses to efficiently manage data across diverse locations.</p>
 
</div>

StorMagic secures funding from Palatine Growth Credit Fund

Platforms to make the most of cloud infrastructure

Cloud Optimization Tools

<div>
 
 <p>In a Series B funding round led by Highsage Ventures, cloud cost management platform Archera raised USD 17 million. Other participants included Ridge Ventures, Amplify Partners, and PSL Ventures.</p>
 <p>The company plans to use this funding to provide more cloud financing and commitment insurance products, support Azure and Google Cloud platforms, expand their team, and enhance financial reporting services for enterprise clients.</p>
 <p>Established in 2019, Archera's platform aids businesses in minimizing cloud expenses and enhancing efficiency by analyzing usage patterns, predicting future costs, and suggesting suitable purchasing strategies for cloud resources. The company boasts of around 400 clients and generates USD 7 million in revenue annually.</p>

</div>

Archera raises USD 17 million in Series B funding for product development and recruitment

<div>

 <p>Alto Neuroscience, a biopharmaceutical company, has been awarded a grant of USD 11.7 million by the Wellcome Trust. This funding is intended to aid the Phase IIb clinical trials of their drug candidate, ALTO-100, which is under investigation as a potential treatment for bipolar depression. The trial is projected to enrol around 200 participants and anticipates revealing primary data by 2026.</p>
 <p>The company specializes in precision psychiatry, using neurobiology to create individualized treatments for various mental health conditions. Through the Precision Psychiatry Platform, Alto Neuroscience utilizes brain biomarkers, such as EEG activity, neurocognitive evaluations, and information collected from wearables, to determine the likely success rate of specific drug candidates among different patients. Its drug development pipeline includes a range of clinical-stage assets, including ALTO-100 and ALTO-300 for major depressive disorder, ALTO-101 targeted at cognitive impairments related to schizophrenia, and ALTO-203 for treating major depressive disorder with anhedonia.</p>

</div>

Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100

<div>
 
 <p>Quest Diagnostics and Becton, Dickinson, and Company (BD) have formed a strategic partnership aimed at developing companion diagnostics (CDx) for enhanced treatment options for cancer and other diseases. BD is an internationally recognized medical technology company that specializes in the development, manufacture, and sale of medical devices, instrument systems, and reagents.</p>
 <p>With a focus on providing a comprehensive solution for the development of CDx, the partnership will be involved in manufacturing and distributing diagnostic kits approved by the FDA. They intend to use flow cytometry technology in the process, which could assist in selecting treatments for patients with cancer. This could potentially improve clinical outcomes and help to reduce healthcare costs.</p>
 
</div>

Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases

Technology providers that enhance satellite operations

Next-gen Satellites

<div>
 <p>Commercial aerospace company, USPACE Technology Group Limited (USPACE), has announced the launch of six commercial optical satellites. They will also be offering different satellite components and services. </p>
 <p>In addition, USPACE revealed their new Hong Kong Satellite Manufacturing Center, along with the details of their optical satellites on their <a href="https://www.uspace.com/categories.html"> website </a>. These satellites vary in range from 0.5 m to 5 m, with prices varying from USD 35,000 to USD 990,000. Future releases will include separation seats, multi-satellite dispensers, and 0.5-meter resolution lightweight cameras.</p>
</div>

USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products

<div>
 <p>Sweden is carrying out the "Stella" study which aims to investigate the possibility of launching a small satellite from a Saab Gripen fighter jet. This is to enhance its operations. The initiative, led by the Swedish Air Force and Defense Research Agency, takes inspiration from Italy's recent plan to launch small satellites via the Eurofighter Typhoon.</p>
 <p>The Swedish Air Force has been notably investing in long-range air-to-ground missile systems for the nation's Gripen C/D fleet. However, no specific details about the budget or financial aspects of this new potential satellite launch strategy have been disclosed.</p> 
</div>

Sweden issues study on Gripen fighter jet’s satellite launch capability

<div>
 <p>On July 15, 2024, Terran Orbital, a satellite solutions and products manufacturer, declared that it received occupancy certification for its new production facility in Irvine, California. Located on a five-acre plot, the factory, with an area of 94,000 sq ft, is anticipated to triple Terran Orbital's space vehicle assembly, integration, and testing capabilities.</p>
 <p>All of Terran Orbital's space vehicle assembly is set to move to the new site to maximize efficiency and capacity usage. This will free up their existing facilities to concentrate on the manufacture of components and modules. The organization also intends to begin cleanrooms construction by 2025.</p>
</div>

Terran Orbital receives certification for new manufacturing facility to begin production

Clean, congestion-free air travel gets liftoff

Passenger eVTOL Aircraft

ANALYST_QUICK_TAKE

<div>
 <p>Crisalion Mobility, a Spanish aircraft manufacturer, has entered into a partnership with UAE's Air Chateau International.</p>
 <p>As part of the agreement, Air Chateau has pre-ordered 10 Integrity eVTOLs, taking Crisalion's pre-orders to 125. The partners will also collaborate to expand eVTOL air taxi services in UAE's major cities.</p>

</div> <p><b>Analyst QuickTake:<br>
 </b> Crisalion Mobility also recently partnered with iJet Aviation in <a href="https:<br>
//sp-edge.com/updates/30665"> June 2024 </a> and Wilbur Air in <a href="https:<br>
//sp-edge.com/updates/31896"> July 2024 </a> to expand its operations and develop the eVTOL air transportation sector in Malaga and Australia.</p>

All Updates

Biogen to acquire Human Immunology Biosciences for USD 1.15 billion to expand its pipeline

Robinhood launches joint investment accounts

eToro partners with London Stock Exchange to expand UK stock offerings

StorMagic secures funding from Palatine Growth Credit Fund

Archera raises USD 17 million in Series B funding for product development and recruitment

Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100

Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases

USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products

Sweden issues study on Gripen fighter jet’s satellite launch capability

Terran Orbital receives certification for new manufacturing facility to begin production

Crisalion Mobility partners with Air Chateau for pre-order of eVTOL aircraft

Precision Medicine

Biogen to acquire Human Immunology Biosciences for USD 1.15 billion to expand its pipeline

Contact us